RareSearch logo

Medana

50+ personnel
Headquartered in Chandler
Established in 2026
Website
Percy Satterfield profile

Percy Satterfield

πŸ‡¬πŸ‡§ United Kingdom

6.5

    Reviewed:

  • - Regulatory Submission
  • - 8 weeks May - July 2024
  • - Pharmaceutical Company

Regulatory submission was incomplete, required additional work.

The initial regulatory submission provided was incomplete, requiring additional work to meet the necessary standards. This resulted in unexpected costs and delays. The team corrected the issues, but it should have been right the first time.

Gwendolyn Kshlerin-Beatty profile

Gwendolyn Kshlerin-Beatty

πŸ‡¨πŸ‡­ Switzerland

9

    Reviewed:

  • - Biomarker Development
  • - 12 weeks October 2023 - January 2024
  • - Research Institution

Efficient and precise biomarker development.

The biomarker development project was managed efficiently, with precise results that met our project objectives. The team's expertise in biomarker research was invaluable, and we were impressed with the quality of the deliverables.

Douglas Macejkovic profile

Douglas Macejkovic

πŸ‡ΊπŸ‡Έ United States

5.6

    Reviewed:

  • - Clinical Data Management
  • - 8 weeks December 2023 - February 2024
  • - Biotech Company

Delayed delivery and lack of communication during the project.

The data management services were delayed, and communication from the team was lacking. It was difficult to get updates, and when the deliverables arrived, they were not as polished as expected. The delays impacted our project timeline significantly.

Eric Stiedemann profile

Eric Stiedemann

πŸ‡°πŸ‡· South Korea

9.3

    Reviewed:

  • - Project Management
  • - 10 weeks July - September 2023
  • - Biotech Company

Seamless project management, results exceeded expectations.

Project management was seamless, and the team exceeded our expectations. They handled all aspects of the project with professionalism and efficiency, keeping us informed every step of the way.

Carla Oberbrunner profile

Carla Oberbrunner

πŸ‡―πŸ‡΅ Japan

6

    Reviewed:

  • - Health Technology Assessment
  • - 8 weeks July - September 2024
  • - Pharmaceutical Company

Health technology assessment was superficial, lacked thorough analysis.

The health technology assessment (HTA) was superficial and did not provide the level of thorough analysis we needed. Some important factors were overlooked, and we had to request additional work to cover these gaps. The overall experience was disappointing.

Drew Ondricka profile

Drew Ondricka

πŸ‡¨πŸ‡³ China

8.9

    Reviewed:

  • - Regulatory Submission
  • - 6 weeks February 2023
  • - Biotech Startup

Professional and knowledgeable, seamless regulatory submission process.

Our regulatory submission was handled with great care and expertise. The process was seamless, and their knowledge of the regulatory landscape was impressive. The team's support was invaluable, and I would not hesitate to use their services again.